レボブノロール

Levobunolol

HCID 39468CAS 47141-42-4
部分構造検索類似構造を探す

基本情報

標準SMILES
CC(C)(C)NC[C@H](O)COc1cccc2c1CCCC2=O
InChIKey
IXHBTMCLRNMKHZ-LBPRGKRZSA-N
分子式
C17H25NO3
平均分子量
291.4 g/mol
単同位体質量
291.18344366

概要

Levobunolol is a cyclic ketone that is 3,4-dihydronaphthalen-1-one substituted at position 5 by a 3-(tert-butylamino)-2-hydroxypropoxy group (the S-enantiomer). A non-selective beta-adrenergic antagonist used (as its hydrochloride salt) for treatment of glaucoma. It has a role as a beta-adrenergic antagonist and an antiglaucoma drug. It is a propanolamine, an aromatic ether and a cyclic ketone. It is a conjugate base of a levobunolol(1+). It derives from a hydride of a tetralin.

名称と識別子

優先名称
Levobunolol
IUPAC
5-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-2H-naphthalen-1-one
現地名
レボブノロール
英語名
LEVOBUNOLOL
分子式
C17H25NO3
分子量
291.39

名称と別名

LEVOBUNOLOL47141-42-4Levobunololum(-)-BunololBunolol, (s)-Bunolol, (-)-G6317AOI7K(S)-5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-1(2H)-naphthalenoneCHEBI:6438DTXSID10438335-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalen-1-one1(2H)-Naphthalenone, 5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-, (S)-
名称をさらに表示
レボブノロール(-)-レボブノロール5-[3-(tert-ブチルアミノ)-2β-ヒドロキシプロポキシ]-3,4-ジヒドロナフタレン-1(2H)-オン(-)-ブノロール5-[3-(tert-ブチルアミノ)-2β-ヒドロキシプロピルオキシ]-3,4-ジヒドロナフタレン-1(2H)-オン5-[(S)-3-[(1,1-ジメチルエチル)アミノ]-2-ヒドロキシプロポキシ]-3,4-ジヒドロナフタレン-1(2H)-オン5-[(2S)-3-[(1,1-ジメチルエチル)アミノ]-2-ヒドロキシプロポキシ]-3,4-ジヒドロ-1(2H)-ナフタレノン5-[(S)-3-(tert-ブチルアミノ)-2-ヒドロキシプロポキシ]-3,4-ジヒドロ-1(2H)-ナフタレノン5-[(2S)-3-(tert-ブチルアミノ)-2-ヒドロキシプロポキシ]-1,2,3,4-テトラヒドロナフタレン-1-オンW 6421AAK-BetaBeteganl-BunololLiquifilmLEVOBUNOLOL USP/EP/BP[(-)-5-[3,(t-Butylamino)-2-hydroxy-propoxy]-3,4-di,HCl5-[3-(tert-Butylamino)-2β-hydroxypropyloxy]-3,4-dihydronaphthalen-1(2H)-one
levobunololoApoLevobunololNovoLevobunololPMSLevobunololApo LevobunololNovo LevobunololPMS Levobunololratio Levobunolol

データベース識別子

CAS
47141-42-4
PubChem CID
39468
DTXSID
DTXSID1043833
ChEMBL
CHEMBL1201237
ChEBI
CHEBI:6438
UNII
G6317AOI7K
Nikkaji
J237.992I

物性

構造計算による物性

XLogP
2.4
極性表面積
58.6 Ų
水素結合供与体数
2
水素結合受容体数
4
回転可能結合数
6
重原子数
21

実験および物理化学的性質

DrugsPharmaceuticals -> Listed in ZINC15
LogP2.1
Solubility2.51e-01 g/L
Human Drugs · 2 件

Breast Feeding; Lactation; Milk, Human; Antihypertensive Agents; Adrenergic Beta-Antagonists; Antiglaucoma Agents; Antiarrhythmics

Pharmaceuticals

Melting Point · 2 件

209-211 °C

209 - 211 °C

Physical DescriptionSolid

物理化学的性質

融点
209 · 209-211°C
貯蔵温度
-20 °C · -20°C Freezer, Under Inert Atmosphere
主な用途
医薬品（低分子化合物）
InChI
1S/C17H25NO3/c1-17(2,3)18-10-12(19)11-21-16-9-5-6-13-14(16)7-4-8-15(13)20/h5-6,9,12,18-19H,4,7-8,10-11H2,1-3H3/t12-/m0/s1
InChIKey
IXHBTMCLRNMKHZ-LBPRGKRZSA-N
SMILES
N(C[C@H](O)COc1c2c(ccc1)C(=O)CCC2)C(C)(C)C

化学的性質

化学的特性White Solid

安全と法規制

毒性情報

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

安全データ

wgk
WGK 3
毒性
LD50 in male, female rats, mice (mg/kg): 700, 800, 1530, 1220 orally; 25, 28, 78, 84 i.v.; LD50 in male, female hamsters, dogs (mg/kg): 435, 500, 100, 100 orally (Kaplan, 1980)
Hazard Classifications
Acute Tox. 4 Oral
ストレージクラス
11 - Combustible Solids

化学と産業

薬理情報

ATC Code · 3 件

S01ED03

S - Sensory organs

QS - Sensory organs

Pharmacodynamics · 1 件

Levobunolol is an ophthalmic beta-blocker, equally effective at β(1)- and β(2)-receptor sites. Levobunolol reduces both elevated and normal IOP in patients with or without glaucoma. In patients with elevated IOP, levobunolol reduces mean IOP by approximately 25-40% from baseline. As the drug is a nonselective &beta-adrenergic blocking agent, it can produce both systemic pulmonary and cardiovascular effects following topical application to the eye. These effects include adverse pulmonary effects (eg. bronchoconstriction, increased airway resistance), and a decrease in blood pressure and heart rate.

Mechanism of Action · 1 件

Levobunolol's mechanism of action in reducing IOP is not clearly defined, but is believed to be due to a reduction of the production of aqueous humor via blockage of endogenous catecholamine-stimulated increases in cyclic adenosine monophosphate (AMP) concentrations within the ciliary processes.

Biological Half-Life20 hours
Metabolism/MetabolitesHepatic
FDA Pharmacological Classification · 5 件

G6317AOI7K

LEVOBUNOLOL

Mechanisms of Action [MoA] - Adrenergic beta-Antagonists

Established Pharmacologic Class [EPC] - beta-Adrenergic Blocker

Levobunolol is a beta-Adrenergic Blocker. The mechanism of action of levobunolol is as an Adrenergic beta-Antagonist.

用途と製造

Use ClassificationPharmaceuticals

応用分野

使用As a non-selective adrenoceptor antagonist, Levobunolol is used as an anticonvulsant.

上流・下流製品情報

サプライヤー14 社

北京华美互利生物化工010-56205725 · [email protected]
杭州摩库生物医药科技有限公司+86-057181025280; +8617767106207 · [email protected]
LGM Pharma1-(800)-881-8210 · [email protected]
安耐吉化学&3A（安徽泽升科技有限公司）021-58432009 400-005-6266 · [email protected]
凯试(上海)科技有限公司021-50135380 · [email protected]
補足説明 · 1 件

定義ChEBI: A cyclic ketone that is 3,4-dihydronaphthalen-1-one substituted at position 5 by a 3-(tert-butylamino)-2-hydroxypropoxy group (the S-enantiomer). A non-selective beta-adrenergic antagonist used (as its hydrochlo ide salt) for treatment of glaucoma.

関連反応

2 件
反応記録を作成

関連ノート

読み込み中…